Patent Examiner Amy Rose Hudson
Art Unit 1636 · Antisense, RNAi, Gene Therapy & Genome Editing · Tech Center 1600 · 396 applications filed 2021–2026
Amy Rose Hudson is a USPTO patent examiner in Art Unit 1636 (Antisense, RNAi, Gene Therapy & Genome Editing) with 396 applications from filing years 2021–2026. Examiner Hudson's allowance rate is 65.0%, below the 82.5% USPTO average for applications filed in the same years. The examiner ranks harder than 78% of examiners. In 2021, decided applications with an examiner interview were allowed 25.7 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1636 · Antisense, RNAi, Gene Therapy & Genome Editing
- Title / gradePrimary Patent Examiner · GS-14
- Service22 years
- PhoneOn each office action
- In USPTO recordsHUDSON, AMY ROSE
Examiner Hudson can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Hudson
- The data favors an interview. Interviewed cases were allowed more often in both measured years, by 25.7 to 34.8 points.
- Plan for the timeline. First office action averages 769 days vs the 622-day USPTO norm.
- Expect a §112. Definiteness & disclosure is the most-issued rejection (199), and applicants overcame it 56.4% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 14.8 to 42.0 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 42 winning responses to Examiner Hudson's §112 rejections that Boundly has classified, 33 (79%) amended the claims and argued, 6 argued without amending, and 3 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Hudson?
Draft your response with Examiner Hudson's record and Art Unit 1636's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 10.0% | 100.0% | 65.2% | +34.8pp |
| 2021 | 22.9% | 94.7% | 69.0% | +25.7pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Hudson.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 10.9% | 80.0% | 38.0% | +42.0pp |
| 2022 | 15.8% | 81.8% | 67.0% | +14.8pp |
| 2021 | 19.3% | 91.7% | 72.3% | +19.4pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/622413 | Von Willebrand Factor (VWF)-Targeting Agents and Methods of Using the Same | Patented | 1 | 🔒 View |
| 17/907833 | Chemically Modified Transfer RNA-Derived Small RNAs (tsRNAs) to Target Pathogenic Bacteria | Patented | 2 | 🔒 View |
| 18/251720 | New Conjugated Nucleic Acid Molecules and Their Uses | Patented | 1 | 🔒 View |
| 18/194203 | Angiotensinogen-Modulating Compositions and Methods of Use Thereof | Abandoned | 2 | 🔒 View |
Art Unit 1636 technology
Frequently asked questions
What is Examiner Amy Rose Hudson's allowance rate?
Is Examiner Hudson a hard examiner?
Do examiner interviews help with Examiner Hudson?
What is Examiner Hudson's most common rejection?
Is an RCE worth filing with Examiner Hudson?
How long until the first office action from Examiner Hudson?
Put Examiner Hudson's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.